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Summary 
T cell dysfunction and thymic involution are major immunologic abnormalities associated with 
aging. Fas (CD95) is a bifunctional molecule that is critical for apoptosis and stimulation during 
T cell development, but the role of Fas during aging has not been determined. Fas expression 
and function on T cells from old (22-26-mo-old)  mice was compared with young (2-mo-old) 
mice and old CD2-Jhs-transgenic  mice. Fas expression and ligand-induced apoptosis were de- 
creased on T cells from old mice compared with young mice. This correlated with an age-related 
increase in CD44+Fas -  T cells. There was a marked decrease in the proliferation of T cells from 
old mice after anti-CD3 stimulation compared with young mice. Anti-CD3-stimulated T cells 
from young mice exhibited increased production of interleukin (IL)-2 and decreased production 
of interferon-q/and IL-10 compared with old mice. There was an age-related decrease in the total 
thymocyte  count from 127  _+  10 cells in young mice compared with 26  +  8  x  106 in old mice. 
In 26-mo-old CD2-~s-transgenic mice, Fas and CD44 expression, Fas-induced apoptosis, T cell 
proliferation,  and cytokine production were comparable to that of the young mice. These results 
suggest that T cell senescence  with age is associated with defective apoptosis, and that the CD2- 
)hs transgene allows maintenance  of Fas apoptosis function and T  cell function in aged mice 
comparable to that of young mice. 
,•e-related 
immune dysfunctions of T cells include thy- 
mic involution (1), decreased  T cell response to mitogens 
or antigens (2-6), altered cytokine expression (7-10), and al- 
tered phenotype (11-13). The decrease in spleen or LN T cell 
responsiveness has been related to an increase in senescent 
memory  T cells (11, D), which exhibit defective phosphory- 
lation after stimulation (14-18). Thymic involution has been 
proposed to be due either to defects in thymocyte  precursors 
derived from stem cells or a defect in expression of thymic 
factors or growth factors required for normal T cell develop- 
ment (19-23).  Recent evidence indicates that depletion  of 
thymocyte stem cells cannot completely account for thymic 
involution with age (24). Evidence to support an age-related 
deficiency of growth factors has been provided by the obser- 
vation that replacement of growth factors or hormones can 
inhibit thymic involution  or T cell dysfunction with aging 
(19-23). 
Fas/Apo-1 (CD95) is a cell surface-signaling molecule that 
mediates apoptosis (25, 26). The apoptosis defect that results 
from defective Fas expression in Ipr mice results in survival 
of self-reactive T cells, loss of self-tolerance, autoimmunity, 
and lymphoproliferation (27). There is a close association be- 
tween apoptosis and proliferation mediated by Fas and other 
apoptosis molecules, including p53 and c-myc  (28, 29). Apop- 
tosis that follows stimulation and proliferation has been pro- 
posed to be critical for the regulation of the T cell response 
to stimuli by removing cells with metabolic defects or au- 
toimmune potential  (30, 31). We propose that this process 
of selective depletion of T cells is necessary throughout the 
life span of the animal to prevent accumulation of dysfunc- 
tional  senescent T  cells. 
This article demonstrates that Fas expression and function 
are decreased in T cells of old mice. Age-related Fas dysfunc- 
tion can be circumvented in CD2-Jhs-transgenic  mice. The 
presence of the CD2-Jas transgene  allows the maintenance 
of thymocyte  numbers in aged mice comparable to that ob- 
served in young mice. The syngeneic mixed lymphocyte  reac- 
tion (SMLtL)  1 and the response of peripheral T cells to stim- 
ulation by CD3 cross-linking is comparable to that of young 
animals. Cytokine expression after stimulation was also com- 
parable to levels observed in young mice. 
Materials and Methods 
Mice.  CD1 mice were obtained from Charles River Breeding 
Laboratories, Inc. (Wilmington,  MA) and kept in specific  pathogen- 
free conditions. 
1 Abbreviation used in  this paper: SMLR, syngeneic mixed lymphocyte 
reaction. 
129  J.  Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/95/07/0129/09 $2.00 
Volume 182  July 1995  129-137 Production of CD2fas Transgenic  CD1 Mic~  CD1 mice were used 
for superovulation and production of the CD2-~s-transgenic mice 
as previously described (32). The CD2-~s construct was made by 
ligation of a full-length murinefls cDNA into an EcoKI site in 
front of exon 1 of a human CD2 minigene consisting of 5.5  kb 
of the 5' flanking sequence,  exon 1, the first intron,  fused exons 
2-5, and 2.1 kb of the 3' flanking sequence. The 3' sequence of 
this CD2 minigene has been shown to be sufficient  to allow copy- 
dependent, integration-independent expression  primarily in CD2 + 
T cells in transgenic mice (33, 34). Transgenic mice were identified 
by tail DNA analysis and housed with littermate controls for 24 
mo while being maintained on food and water ad libitum.  The 
young 2-mo-old CD1 mice used in the experiments were derived 
from a breeding colony of CD1  mice. 
Southern Blot Analysis.  Tail DNA was prepared and digested 
with the indicated restriction enzymes. Approximately 10 #g of 
the digested DNA was separated on a 0.7% agarose gel, blotted 
to a nylon membrane, and hybridized with a 32p-labeled full-length 
Jhs cDNA probe extending from 49 to 1,033 bp of the murine se- 
quence as previously described (32). 
Expression ofMurine Fas Ligand.  The murine Fas ligand was 
cloned and sequenced using PCP, primers that were prepared ac- 
cording to the sequence of the known mouse Fas ligand (35, 36). 
The full-length  murine  Fas ligand  cDNA was cloned  into  the 
pcDNA1 expression vector (Invitrogen,  San Diego, CA).  20 gg 
of purified  plasmid DNA  was precipitated  with  500  gg/ml of 
DEAE-Dextran (Sigma Chemical Co., St. Louis,  MO), added to 
5  x  106 COS7 cells in a 10-cm cell culture dish containing 10 ml 
of serum-free RPMI 1640 and 10 mM chloroquine (Sigma Chem- 
ical Co., St. Louis, MO), and incubated at 37~  for 4 h. The trans- 
fected cells were then treated with  10% DMSO  +  RPMI 1640 
for 2 min, and grown in 12% FCS  +  tLPMI 1640 for 72 h. The 
supernatant  was collected and then stored at  -20~  until use. 
Preparation of Murine Fas-Human IgG1 Fusion Protein.  A mu- 
rine Fas-human IgG1 (fas-hlg) fusion protein was prepared as pre- 
viously described (37). Briefly, the extracellular domain of the mouse 
Jhs cDNA was fused with the Fc portion of human IgG1 gene to 
form an open reading frame. The fusion gene was cloned into the 
pcDNA1 eukaryotic expression vector (Invitrogen) and transfected 
into COS7 cells as described above. The fusion protein was purified 
on an anti-human IgG agarose column (Sigma Chemical Co.) and 
concentrated to  1 mg/ml in PBS. 
T Cell Enrichment.  Single-cell  suspensions of lymphocytes or 
spleen cells were enriched using a T cell enrichment column (K&D 
Systems,  Inc., Minneapolis,  MN) according to the directions of 
the manufacturer. Purified T cell populations were >98% T cells 
as determined by flow cytometry analysis  of CD3 expression. 
Flow Cytometry Analysis.  Anti-CD3  (clone:  145.2Cll),  anti- 
CD4  (clone:  GK 1.5),  anti-CD8  (clone:  53-47)  and  anti-CD44 
(clone: 1M7), and anti-mouse Fas (clone: Jo2) were purchased from 
PharMingen (San Diego, CA). Single cell suspensions of lympho- 
cytes, spleen cells, or thymocytes (10  6 per sample) were stained in 
FACS  |  buffer (PBS with 5% FCS and 0.1% sodium azide; Becton 
Dickinson & Co., Mountain View,  CA) and optimal concentra- 
tions of antibodies. For two- and three-color analyses, cells were 
labeled with optimal concentrations of FITC-conjugated anti-CD4 
and PE-conjugated anti-CD8 or biotin-conjugated anti-Fas or anti- 
CD44.  Biotintylated  conjugated  antibodies  were  revealed  by 
Tandem-avidin. Viable cells were determined by forward and side 
light scatter using standard methods and were <6% of the sample 
size. Viable cells (10,000 per sample) were analyzed by flow cytom- 
etry on a FACScan |  (Becton Dickinson & Co.) with logarithmic 
scales. 
Stimulation by SMLR or Anti-CD3.  Anti-CD3 (clone 145.2Cll) 
mAb was diluted to 1 #g/ml and coated on flat-bottom 96-well 
plates (Costar Corp., Cambridge, MA) by incubation for 12 h at 
4~  The plates were thoroughly washed using sterile PBS, and 
enriched T cells were added in duplicate cultures for 72 h. For SMLK 
proliferative responses, 106 enriched T cells were cultured in 200 #1 
of KPMI supplemented with  10%  FCS.  For some experiments, 
the SMLK was carried out in the presence of the Fas fusion protein 
(0.1 gg/ml) or plate-bound anti-mouse Fas mAb (1 #g/ml). Prolifer- 
ation was determined at different time points by a 12-h pulse of 
1 gCi [3H]TdK (Amersham Corp., Arlington Heights,  IL), and 
[3H]TdR uptake was measured by liquid scintillation  counting. 
Assay of Cytokines.  Cytokines were assayed using ELISA kits 
according to the manufacturer's instructions (Genzyme Corp., Cam- 
bridge,  MA).  The OD4os was measured on a microplate reader 
(Emax; Molecular Devices Corp.,  Menlo Park,  CA).  Duplicate 
samples were assayed in three separate  experiments and the mean 
was determined. The statistical significance was determined using 
the Wilcoxon sign-rank nonparametric test. 
In Situ Nick Translation  Apoptosis Staining.  Nuclear DNA frag- 
mentation was carried out as previously described (38).  For cell 
suspensions,  10  s cells  were  cytospun  onto  poly-r-lysine (Sigma 
Chemical Co.) -precoated slides. The slides were fixed for 30 min 
in  10%  formalin-PBS  buffer  and  then  washed  with  H20  for 
2 min, six times. Fresh proteinase K (20 gg/ml; Boehringer Mann- 
heim Corp., Indianapolis, IN) was added onto the slides and in- 
cubated  at  room temperature  for  15  min.  After washing  with 
H20, terminal deoxynucleotide transferase (TdT) (1 U/ml; Boeh- 
ringer Mannheim Corp.)  and digitonigen-modified dUTP (0.15 
/zl/ml; Boehringer Mannheim Corp.) was added in TdT buffer. A 
coverglass  was applied and the slides incubated for 1 h  at 37~ 
in a humidified chamber. After removing the coverglass,  the slide 
was washed once with PBS, followed by incubation in 5% BSA/ 
FACS  |  buffer for 15 min at room temperature. The slides were 
incubated with an antidigoxigenin antibody conjugated to alka- 
line phosphatase (Boehringer Mannheim Corp.) at 1:50 dilution 
with FACS  |  buffer for 30 min at room temperature. After washing 
six times in PBS, the slides were incubated in alkaline phosphatase 
buffer  with  5-bromo-4-chloro-3-indolyl  phosphate/nitro  blue 
tetrazolium (BCIP/NBT) (Sigma Chemical Co.) and incubated for 
30 min at room temperature. 
Statistical Analysis.  Statistical analysis of proliferation and apop- 
tosis after SMLK or anti-CD3 stimulation was carried out using 
the analysis  of variance model at each time point. 
Results 
CD2-fas-transgenic  Mice.  Tail DNA  was prepared  from 
mice at 4  wk  of age,  digested  with  EcoKI restriction  en- 
zyme, and hybridized with the full-length mouse Fas cDNA 
probe. One of the four founder CD1 CD2-fas-transgenic mice 
was identified as having a single 1.1-kb transgenic Fas cDNA 
integration band (Fig.  1, lane 3) and therefore mated with 
CD1 breeder mice. Transgenic and nontransgenic  offspring 
of this  mating were  studied  at ages 22-26  mo. 
Fas Expression and Function on Lymphocytes.  Cell surface 
Fas expression was decreased on lymphocytes from 26-mo- 
old nontransgenic CD1 mice compared with 2-mo-old non- 
transgenic  mice  (Fig.  2).  Fas  expression  was  increased  to 
youthful levels in 26-mo-old CD1 CD2-fas-transgenic mice. 
Fas ligand-induced apoptosis was markedly decreased in LN 
130  T Cell Apoptosis and Aging Figure  1.  Analysis  of  CD2-~s- 
transgenic  CD1 mice by Southern blot 
analysis.  Tail  DNA was digested with 
the EcoRI restriction enzyme, which 
releases the 1.1-kb.~s  cDNA insert 
from CD2-~s-transgenic mice. 
cells from aged mice, and development of this apoptosis de- 
fect was prevented in CD2-J~s-transgenic aged mice (Fig. 3). 
Syngeneic Mixed Lymphocyte Response.  Spleen cells from 
2-mo-old mice exhibited a weak SMLR characterized by a 
minimal proliferative response (Fig. 4 A). This was not caused 
by an absence of IL-2 since the cells were cultured in the pres- 
ence of 50 U/ml of Ib2. In contrast,  there was a statistically 
significant increased proliferative response  (p <0.001)  after 
SMLR which peaked at 96 h using enriched spleen T cells 
of 26-mo-old mice. The SMLR response of spleen cells from 
26-mo-old CD2-~s-transgenic mice was similar to that ob- 
served in 2-mo-old mice.  On days 1 and 3 of the SMLR, 
Correction of Fas-ligand Induced Apoptosis 
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Figure 3.  Correction of Fas ligand-induced apoptosis in CD2fas-trans- 
genic aged mice. Lymphocyte suspensions (106 per sample) were cultured 
for 18 h with different dilutions of supernatant of COS7 cells expressing 
the Fas ligand ranging from 0 to 0.5 (50:50 vol/vol). Lymphocytes were 
obtained from 2- (U), 22- (O), or 22-mo-old CD2-fas-transgenic  mice 
(A). Apoptosis was determined by the in situ nick translation assay of 
single-cell suspensions of lymphocytes as previously described (50). The 
results represent the mean _+ SEM for three separate mice assayed  individ- 
ually in triplicate culture wells. 
there was minimum apoptosis (20-30%) in all three groups 
of mice (p <0.05). However, on days 5 and 7, apoptosis in- 
creased to 60-70% of spleen cells in both 2- and 26-mo-old 
CD2-fas-transgenic mice (Fig. 4 B). In contrast, the percentage 
of cells undergoing apoptosis remained significantly lower 
in aged mice on days 5 and 7 of the SMLR (p <0.001). 
THYMUS 
2-mo-old  26-mo-old  26-mo-old  Tg 
.....  ,,;  .....  ........  ,,  ........ 
FAS 
25~ 
11% 
Z  :".,/  89% 
￿9  .~i  /~ 
:i/:  i::  i 
SPLEEN 
I  .~ :60% 
"J0 .....  i~,  ' 
40% 
1 
￿9  f  " 
,J  \ 
FAS 
Figure 2.  Expression  of Fas on 
thymocytes  and spleen  celk Single- 
ceU suspensions of thymocytes and 
spleen cells from 2-mo-old,  26- 
mo-old, and 26-mo-old Fas-trans- 
genic mice (106 per sample) were 
stained with anti-Fas. The histo- 
grams of Fas expression are repre- 
sentative of at least 10 mice from 
each group. The gates used to de- 
fine lymphocyte populations  are 
indicated  by  the  vertical  lines. 
Negative control staining is shown 
as the dotted curves. There was 
a statistically significant increase 
in Fas- cells in the groups of 26- 
mo-old mice compared with 2-mo- 
old and 26-mo-old Fas-transgenic 
mice  (p  <0.01).  Viable  cells 
(10,000 per sample) were analyzed 
by flow cytometry on a FACScan  | 
with logarithmic scales. 
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Figure 4.  Effect of anti-Fas and Fas fusion protein on SMLR-induced 
proliferation and apoptosis. Lymphocyte suspensions (106 per sample) were 
cultured in 96-well plates in the presence oflb2 (50 #m/ml). The prolifer- 
ation was determined at the indicated times by [3H]thymidine incorpo- 
ration and apoptosis determined by the in situ nick translation method. 
(A) SMLR proliferative response. (B) Apoptosis of SMLR stimulated cells. 
(C) SMLR proliferative response in plates that had been precoated with 
anti-mouse Fas antibody (1 #g/ml). (D) Apoptosis of SMLR-stimulated 
cells carried out on plates precoated with anti-mouse Fas (1 #g/ml). (E) 
SMLR proliferative response in the presence of Fas fusion protein (FasFP; 
0.1 Fg/ml). (F) Apoptosis of SMLR-stimulated cells carried out in the 
presence of Fas fusion  protein (0.1 #g/ml). -I--,  2-too-old; ---0-, 26- 
mo-old; -/g--, 26-mo-old transgenic. 
To determine if the cells undergoing SMLR were sensitive 
to Fas mediated apoptosis, SMLR was carried out in the pres- 
ence of 1 #g/ml of purified anti-Fas antibody. Anti-Fas anti- 
body did not prevent the SMLR proliferative  responses by 
spleen cells from 26-mo-old nontransgenic mice and had no 
effect on the percentage of cells undergoing apoptosis (com- 
pare Fig. 4, A  and B with Fig. 4,  C  and D). Blocking of 
the Fas-Fas ligand interaction during SMLIL with a Fas fu- 
sion protein resulted in a statistically  increased proliferative 
response and decreased apoptosis in young 2-mo-old mice 
and in 26-too-old CD2-fas-transgenic mice (Fig. 4, E  and 
F) (p <0.001). In contrast, the SMLR and apoptosis responses 
from 26-mo-old mice was not significantly affected by the 
presence of Fas fusion protein (p >0.05). These results indi- 
cate that the increased SMLR exhibited by spleen cells from 
26-mo-old mice is associated with defective Fas signaling and 
apoptosis,  which is present in 2- and in 26-too-old CD2- 
)~s-transgenic mice, and that the increased SMLR in aged 
mice is caused by a defect in apoptosis.  This failure could 
not be corrected by stimulation with anti-Fas antibody, con- 
sistent with the finding that Fas expression is defective on 
T  cells from aged mice. 
Prevention of Age-related Decrease in Proliferation and Apop- 
tosis in CD2fas-transgenic  M/ca  T cell proliferation after anti- 
CD3 cross-linking peaked at 72 h in 2-too-old CD1 mice 
(Fig. 5 A). In contrast, T cells from 26-mo-old mice exhibited 
a  statistically  significant  decreased  proliferative  response 
(p <0.01)  on days 2-4  after  anti-CD3 cross-linking and a 
statistically  significant  increase (p <0.01) on days 5-7 after 
anti-CD3 cross-linking. The anti-CD3 proliferative responses 
in 26-too-old CD2-Jas-transgenic mice (and 2-mo-old CD2- 
fas-transgenic mice, data not shown) were significantly de- 
creased ~  <0.01) but similar to those observed in 2-mo-old 
mice with peak proliferation on day 3 followed by a decrease 
in proliferation. Apoptosis after anti-CD3 stimulation was 
significantly increased (p <0.01) in 2-mo-old CD1 mice and 
in 26-too-old CD2-~s-transgenic mice compared with 26- 
mo-old nontransgenic mice (Fig.  5 B). 
Correction of Cytokine Response in CD2-fas-transgenic Aged 
M/co  Decreased Ib2 production after anti-CD3 cross-linking 
has been noted in old mice and humans (3-5). The 50% de- 
crease in I1-2 production after anti-CD3 cross-linking in 22- 
mo-old mice was partially corrected in 22-mo-old CD2- 
.~s-transgenic mice (Fig. 6 A). There was an increase in IL-4 
production on days 2 and 4 after anti-CD3 cross-linking in 
aged mice compared with 2-mo-old mice, and this increase 
was partially prevented in 22-too-old CD2-fas-transgenic mice 
(Fig. 6 B). There was also an increased production of IL-10, 
which peaked on day 6 in 22- and 2-mo-old mice in response 
to anti-CD3 cross-linking (Fig. 6 C). This increased Ibl0 
production was prevented in CD2-fas-transgenic  mice. These 
results indicate that the aged mice exhibit a shift toward a 
Th2-type cytokine response (IL-4, Ibl0) rather than a Thl 
cytokine response (IL-2), and that this shift can be prevented 
in CD2-J~s-transgenic  aged mice. 
Correction of CD44 Expression on  Thyraocytes and Spleen 
Cells.  Thymocyte subpopulations exhibiting defective Fas 
expression  were primarily  CD4 +CD8 +  (double-positive) 
and CD4-CD8-  (double-negative) thymocytes in 26-mo- 
old nontransgenic CD1 mice (Fig. 7 A). Most of the thymo- 
cytes with low Fas expression exhibited increased expression 
of CD44. Thymocytes from 26-mo-old CD2-fas-transgenic 
mice were phenotypically similar  to those from 2-mo-old 
mice. Less than 20% of enriched T cells from the spleen of 
2-too-old nontransgenic mice express  CD44,  and "~90% 
were Fas +. In 26-too-old nontransgenic CD1 mice, 60% of 
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Figure  5.  Correction of prolifera- 
tion and apoptosis after CD3 stimu- 
lation  in  aged  CD2-fis-transgenic 
mice. Lymphocyte suspensions (106 
per sample) were cultured in 96-well 
plates that had been precoated with 
anti-CD3 (10 #g/ml). (A) The prolif- 
eration was determined at the indi- 
cated times by the [3H]thymidine in- 
corporation assay. (B) Apoptosis was 
determined by the in situ nick transh- 
tion assay  of single-cell suspensions of 
lymphocytes as previously described 
(50). The results represent the mean 
_+ SEM for three separate  mice assayed 
individually in triplicate culture wells. 
enriched spleen T cells were Fas-, and '~80% were CD44 +. 
In 26-mooold Fas-transgenic  mice, expression of CD44, CD4, 
and Fas was similar to that observed in 2-mo-old mice. 
Prevention of Thymic Involution in Aged CD2-fas-transgenic 
Mice.  There was a  markedly decreased  number  of thymo- 
cytes in 22-mo-old CD1 mice compared with 2-mooold CD1 
mice, which was prevented in the presence of the 22-too-old 
CD2-fas-transgenic mice (Fig. 8 A). Consistent with the finding 
of increased  thymocyte  numbers  in  young  and  aged  CD2 
Fas-transgenic  mice,  thymocyte apoptosis  was  decreased  in 
young and  aged CD2-fas-transgenic  mice on days 2-6  after 
CD3 cross-linking (Fig. 8 B). In contrast, in 22-mo-old mice, 
there was increased  apoptosis on days 2-6  after CD3  cross- 
linking,  suggesting high utilization of programmed cell death 
mechanisms within  the  aged thymus.  These results indicate 
that the CD2-fas transgene might provide an intrathymic signal 
for thymic development,  thereby preventing  apoptosis  after 
CD3  cross-linking  in vitro. 
Discussion 
The immunologic mechanism underlying defective  Fas func- 
tion with age is not known. One possibility is that there is 
an intrinsic age-related defect in transcriptional or the post- 
transcriptional factors that regulate Fas expression. This view 
is supported by the fact that Fas is a member of a family of 
receptors that contain cysteine repeat domains and this family 
of receptors includes TNF-R and CD40-L, which also exhibit 
decreased expression with age (39-41). Another possibility is 
that the Fas signaling-function might be impaired with aging, 
which could further accentuate an expression defect. Fas sig- 
naling involves a phosphatase dependent pathway, which is 
decreased  with aging (42). Further investigation  into the mech- 
anisms of defective  Fas signaling with aging could lead to novel 
intervention  therapies to restore normal Fas signaling. 
Our data indicate that Fas function is decreased more than 
Fas expression in old mice. One possibility is that high Fas 
expression is required for Fas-induced apoptosis. Enforced up- 
regulation of Fas in the CD2-.~s-transgenic  mice allows the 
maintenance of Fas function and production of Fas-sensitive 
T cells in aged mice. This dissociation of Fas expression and 
function has also been observed in the thymus, where all cells 
express intermediate to high levels of Fas, but not all thymo- 
cytes are sensitive to Fas-induced  apoptosis (Zhou, T., P. Yang, 
Z. Wang, andJ. D. Mountz, manuscript submitted for pub- 
lication). Another possibility may be that alternatively spliced 
or nonfunctional forms of the Fas molecule might be present 
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Figure  6.  Correction of cyto- 
kine production  after anti-CD3 
cross-linking in  aged CD2-~s- 
transgenic mice. Lymphocyte  sus- 
pensions (2  x  106 cells per mt) 
from 22-mo-old mice were cul- 
tured in 24-well plates that  had 
been precoated  with anfi-CD3 (10 
/~g/ml). Cytokine concentrations 
were determined at the indicated 
times by ELISA. (A) I1:2 after 2-(t 
culture. (B) II.-4 after 2- and 4-d 
culture. (C) 1I:10 at 2-8-d culture. 
Each data point represents the av- 
erage of five mice per group, and 
the error bars represent the SEM. 
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Figure 7.  Correction  of CD44 expression 
on thymocytes and spleen cells in aged CD2- 
J~s-transgenic mice. Single-cell suspensions of 
thymocytes and spleen cells from 2-, 26-, and 
26-mo-old  Fas-transgenic  mice  (106 per 
sample) were analyzed for expression of CD4 
and/or CDS, Fas, and CD44. (A) Thymocytes 
were labeled with anti-Fas,  anti-CD4, and anti- 
CD8,  or anti-Fas and anti-CD44. Fas  + and 
Fas- thymocyte populations are defined as in 
Fig. 2. (B) Enriched spleen T cells were labeled 
with anti-CD44, anti-CD4, and anti-Fas. The 
gates used to define lymphocyte populations 
are indicated  by the vertical  and horizontal lines. 
Viable cells (10,000 per sample) were analyzed 
by flow cytometry on a FACScan  |  with loga- 
rithmic scales. A 
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Figure  8.  Thymocyte  call count and apoptosis after 
anti-CD3 cross-linking. Single-cell  suspensions  of thymo- 
cytes were prepared from 2-, 22-, or 22-mo-old CD2- 
J~s-transgenic mice. Thymocyte suspensions (106 per 
sample) were cultured in 96-well plates that had been 
precoated with anti-CD3 (10 #g/ml). (A) Total number 
of thymocytes.  (B) Percentage  of thymocytes  undergoing 
apoptosis at different time points after CD3 stimula- 
tion as determined by the in situ nick transhtion method. 
Each data point represents the average of five mice per 
group, and the error bars represent the SEM. 
on T cells from aged mice, and that these forms can interact 
with the Fas antibody but do not signal apoptosis. We have 
reported the presence of an alternatively spliced Fas molecule 
that results in the secretion of soluble Fas and inhibition  of 
apoptosis (37). Additionally, other investigators have reported 
a mutation of Fas leading to defective apoptosis signaling in 
CBA/ HeN-llor/Ipr  mice (27). 
Previous results indicate that there are at least two pathways 
for apoptosis of thymocytes (28, 29, 43). Apoptosis of thymo- 
cytes that have undergone DNA damage by x-irradiation re- 
quire p53,  whereas steroid-induced  apoptosis does not.  In 
the Fas-mutant llor  mice, there is an increase in steroid-induced 
apoptosis of thymocytes, but a decrease in Fas-induced apop- 
tosis caused by the Fas mutation  (44).  The present  results 
also indicate that there is more than one pathway for apop- 
tosis of T cells in the thymus and LN. One is active in young 
mice,  whereas a second Fas-independent  pathway is active 
for deletion of T cells from aged mice after stimulation. The 
shift from Fas-dependent to Fas-independent apoptosis with 
aging may account for altered phenotype and function of T 
cells with  aging. 
Loss of Fas function with age is associated with a decrease 
of the Thl cytokine IL-2 and an increase of the Th2 cytokines 
II,-4 and IL-10. The overuse of the Th2 pathway with aging 
has also been previously reported by other investigators (45, 
46). We have shown recently that T cells that have been stimu- 
lated to undergo preferential development since Thl T cells 
express Fas and Fas ligand, whereas T cells stimulated to un- 
dergo development as Th2 T cells do not express Fas or Fas 
ligand (Zheng,  R., J. Pan, J. Mountz,  T. Zhou, and C. T. 
Weaver, manuscript submitted for publication). The shift of 
Thl to Th2 T  cells with aging may be caused by defective 
Fas-Fas ligand signaling.  The restoration of preferential de- 
velopment of Thl cells by theJas transgene in aged mice sug- 
gests that Fas interaction with its ligand has been corrected, 
and that Fas interaction may play a critical role in T cell de- 
velopment  as well as T  cell apoptosis with  aging. 
Immune system aging is associated with an increase in per- 
centage of memory T cells characterized by expression of CD44 
and CD45RO (11-13,  47-50). In 26-mo-old nontransgenic 
mice, approximately one third of thymocytes and 50-60% 
of purified spleen T cells, increased CD44 expression was as- 
sociated with  low  expression  of cell surface Fas.  CD44 + 
memory T cells would therefore be insensitive to Fas-induced 
apoptosis. The percentage of CD44 + T cells was greatly re- 
duced in CD2-J~s-transgenic aged mice. These results indi- 
cate that  development of CD44 + memory T  cells  in aged 
mice is related to several aspects of cell development, including 
Fas expression. In both the spleen and thymus, there was also 
a small population of cells that express high Fas and also high 
CD44, indicating  that  other factors in addition  to Fas ex- 
pression influence CD44 expression. 
Rescue of thymocytes from apoptosis by the provision of 
necessary signaling molecules or growth factors may be an 
important  mechanism  in the restoration of T  cell function 
with aging. This is consistent with a number of reports that 
certain growth factors, including growth hormone from trans- 
planted pituitary glands (23), can prevent age-related thymic 
atrophy.  Fas has been proposed to serve as a costimulatory 
molecule during thymic development of T cells (51), and our 
data show that decreased Fas expression and function with 
age leads to increased apoptosis of thymocytes. These results 
were unexpected because Fas was first identified as a mole- 
cule capable of inducing  apoptosis in certain cell lines (25, 
26). However, it is likely that Fas signaling leads to different 
responses, depending on the cell type and stage of differenti- 
ation.  In support of this,  in Fas-defective lpr/Ipr mice, and 
Fas ligand-defective gld/gld mice, defective apoptosis of thymo- 
cytes has been difficult to detect (52), and the primary defect 
in these mice is abnormal T cell differentiation and tolerance 
loss (53, 54). Therefore, we propose that defective intrathymic 
Fas signaling with age leads to a developmental defect and 
increases thymocyte apoptosis by a Fas-independent pathway, 
and that defective Fas signaling plays a major role in develop- 
ment  of thymic atrophy with  aging. 
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